Notably, Fn14 overexpression was selectively associated with a poorer relapse-free survival in TNBC and HER2 patients but not in patients with ER-positive BCs (Supplementary Fig. 2), suggesting that TWEAK/Fn14 signalling may trigger subtype specific responses in BC patients. The gene discussed is ERBB2; the disease is breast cancer.